It ought to be mentioned that by the end of the 7-12 months Extension period, patients were older and, thus, at higher fracture risk compared with the first 3?years of FREEDOM, potentially underestimating the fracture risk reduction observed with denosumab treatment in this longitudinal study without a parallel comparator arm
It ought to be mentioned that by the end of the 7-12 months Extension period, patients were older and, thus, at higher […]